Excelsior Sciences just locked in a $95M reminder that the future of drug discovery is no longer a slow waltz through a decade of pipetting. It is an engineered sprint built on chemistry that refuses to wait, AI that refuses to guess, and leadership that refuses to accept the industry’s glacial tempo as a law of physics. Watching this team rise out of Cure at 345 Park Avenue South feels like seeing a new American industrial engine roar to life, one floor above the Flatiron streets and several floors above anyone still clinging to legacy discovery timelines. Michael Foley walked out of 3 decades of biotech trenches not to retire but to finally build the system he wished he had back at Broad, Tri I TDI, FORMA, and CombinatoRx. Martin D. Burke brought the modular chemistry that behaves like a programmable language instead of an artisanal craft. Bartosz Grzybowski brought the computational firepower that turns synthesis planning into something closer to inevitability. Jana Jensen welded it all together so the science does not drift into academic fantasy.
The cap table reads like a cross section of conviction. Deerfield Management, Khosla Ventures, and Sofinnova Partners co-led a $70M Series A that does not smell like speculation. Cornucopian Capital and Illinois Ventures joined with MIT and Princeton, and Eli Lilly stepped in with a signal that lands harder than any press quote. A pharma giant dropping $27B into US-based small molecule manufacturing does not invest here by accident. Add a $25M Empire State Development grant and suddenly private capital, public capital, and industrial capital are all pointing at the same truth. The US cannot rebuild secure pharmaceutical supply chains without rebuilding domestic chemistry, and Excelsior Sciences is handing industry a path forward.
Everything revolves around the Smart Bloccs platform. Burke’s MIDA/TIDA chemistry becomes a machine readable alphabet. Grzybowski’s algorithms become the translation layer. Automated synthesis, multiplexed assays, and ML driven closed loops collapse discovery cycles from months to weeks while generating data that compounds like interest. Starting from ~2,000 FDA approved molecules means they are not gambling on novelty but engineering from probability. It is chemistry that machines can perform cleanly, predictably, and at a speed that shifts the economics of the entire sector.
The pitch to pharma and biotech is deceptively simple. Faster synthesis, higher success rates, onshore reliability, and a contract model that fits the reshoring wave already pushing more than $250B across the industry. When Michael Foley talks about applying the platform to an internal program within year one, it lands less like ambition and more like operational math.
Startups Startup Funding Venture Capital Series A AI Automation Biotech Pharmaceutical Chemistry ChemTech Healthcare HealthTech Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem
